● GlobeNewsWireNov 11, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Nurix Therapeutics Appoints Arati V. Rao, M.D., as Chief Medical Officer
Physician-scientist and oncology leader brings more than two decades of experience in academic medicine, global clinical development and regulatory submissions Physician-scientist and oncology leader brings more than two…
● GlobeNewsWireNov 10, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Nurix Therapeutics to Participate in Upcoming Investor Conferences
BRISBANE, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degr…
● GlobeNewsWireNov 5, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition
BRISBANE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degr…
● GlobeNewsWireNov 3, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Nurix Therapeutics Announces Sanofi's Decision to Discontinue Development of STAT6 Degrader SAR448272
BRISBANE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines, today announced that Sanofi notif…
Nurix: Maintaining 'Strong Buy' Updated Bexobrutideg Data CLL/SLL And Multiple Advancement Pathways
Nurix Therapeutics is maintained at "Strong Buy" due to pivotal progress with bexobrutideg, robust partnerships, and strong financials. The company initiated the phase 3 DAYBreak CLL-306 study, aiming to demonstrate bexo…
● Zacks Investment ResearchOct 12, 2026 · 18:26 ETEARNINGS EXPECTED BY FEB 1
Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass Estimates
Nurix Therapeutics, Inc. (NRIX) came out with quarterly earnings of $4.73 per share, beating the Zacks Consensus Estimate of a loss of $0.56 per share. This compares to a loss of $1.03 per share a year ago.…
● GlobeNewsWireOct 7, 2026 · 01:00 ETCOMPANY'S OWN WORDS
Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia
First patient enrolled in cohort combining bexobrutideg with venetoclax Initial cohort to focus on relapsed/refractory CLL, with potential expansion to first-line CLL Strategy includes evaluation of bexobrutideg given in…
● GlobeNewsWireOct 5, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences
Two-year extension builds on productive relationship established in 2019 Nurix continues to retain co-development and 50/50 profit sharing options on up to two programs in the United States BRISBANE, Calif., Oct. 05, 202…
● GlobeNewsWireSep 29, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer
BRISBANE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein deg…
● Defense WorldSep 25, 2026 · 03:23 ETEARNINGS EXPECTED BY FEB 1
842,089 Shares in Nurix Therapeutics, Inc. $NRIX Bought by Bank of America Corp DE
Bank of America Corp DE acquired a new stake in shares of Nurix Therapeutics, Inc. (NASDAQ: NRIX) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission.…
● Zacks Investment ResearchSep 9, 2026 · 13:00 ETEARNINGS EXPECTED BY FEB 1
Nurix Therapeutics (NRIX) Upgraded to Buy: Here's Why
Nurix Therapeutics (NRIX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.…
● GlobeNewsWireSep 1, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Nurix Therapeutics to Participate in Upcoming September Investor Conferences
BRISBANE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein deg…
Nurix Therapeutics: Roche Has Changed The Economics Of The Bull Case
Nurix secures a transformative Roche partnership, gaining $700M upfront, 50% U.S. profit share, and 60% Roche-funded global development for bexobrutideg. NRIX's financial runway is extended to ~3.5 years, reducing near-t…
● GlobeNewsWireAug 20, 2026 · 07:00 ETCOMPANY'S OWN WORDS
Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer
BRISBANE, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein degradation medicines for patients with cancer and infla…
Article counts from the last market-wide feed page, across every symbol we track and not just NRIX · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.
The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.